Background: Inflammatory bowel diseases (IBDs) represent a group of chronic immune-mediated disorders that are influenced by a genetic predisposition and additional environmental triggers. Genome-wide association studies strongly implicate that a number of immune system-related genetic variations are critically contributing to the initiation and promotion of intestinal inflammation. Especially the identification of the strong association of a series of single nucleotide polymorphisms including interleukin (IL)-23R, CCR6, signal transducer and activator of transcription 3 (Stat3) and Stat4 with IBD susceptibility point at a critical involvement of T cells and especially of IL-17a-producing Th17 cells in the immune pathogenesis of IBD. In line with this hypothesis, a series of preclinical studies have unequivocally established that T cells are key drivers of immune-mediated colitis. Interestingly, especially Th17 cells were identified to be highly prevalent in inflamed IBD tissues, a finding that seems to be functionally relevant as genetic inactivation studies in the mouse resulted in almost complete suppression of colitis development. Key Messages: While targeting Th17 cell differentiation regulating transcription factors, as retinoic acid-related orphan receptor gamma t (RORγt) is effective in preventing murine colitis, one concern of drugs targeting RORγt in a clinical setting represents the large body of murine data unambiguously demonstrating that additional pathways within and outside the immune system are equally RORγt-dependent increasing the risk of undesirable side effects. The AP1 transcription factor Batf (B cell-activating transcription factor) appears to exclusively regulate pathways within lymphocytes. Importantly, Batf represents a central regulator of Th17 cell development and is strongly upregulated within IBD-affected tissues. Employing 2 acute colitis models, we demonstrate in this study that Batf-expressing T cells are critical drivers of T cell-mediated colitis while in contrast to Stat3 loss of Batf does not affect intestinal epithelial cell homeostasis ex vivo. Conclusions: Targeting Batf in IBD emerges as an attractive therapeutic approach disabling colitogenic T cell activities while sparing off-target effects in the intestinal epithelial cell compartment.

1.
Strober W, Fuss I, Mannon P: The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117:514-521.
2.
Duerr RH, et al: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-1463.
3.
Raine T, Liu JZ, Anderson CA, Parkes M, Kaser A: Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated disease. Gut 2015;64:250-259.
4.
Neurath MF: Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329-342.
5.
Neurath MF: New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol 2014;7:6-19.
6.
Chen ML, Sundrud MS: Cytokine networks and T-cell subsets in inflammatory bowel diseases. Inflamm Bowel Dis 2016;22:1157-1167.
7.
Mosmann TR, Coffman RL: Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46:111-147.
8.
Jiang W, et al: Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res 2014;63:943-950.
9.
Gerlach K, et al: TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol 2014;15:676-686.
10.
Nalleweg N, et al: IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut 2015;64:743-755.
11.
Leung JM, et al: IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 2014;7:124-133.
12.
Neurath MF, et al: The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002;195:1129-1143.
13.
Ivanov II, et al: The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126:1121-1133.
14.
Leppkes M, et al: RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009;136:257-267.
15.
Mudter J, et al: The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest 2008;118:2415-2426.
16.
Hueber W, et al: Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-1700.
17.
Krug N, et al: Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 2015;372:1987-1995.
18.
Schraml BU, et al: The AP-1 transcription factor Batf controls T(H)17 differentiation. Nature 2009;460:405-409.
19.
Tussiwand R, et al: Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 2012;490:502-507.
20.
Bollrath J, et al: gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15:91-102.
21.
Schlitzer A, et al: IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013;38:970-983.
22.
Eberl G, Littman DR: Thymic origin of intestinal alphabeta T cells revealed by fate mapping of RORgammat+ cells. Science 2004;305:248-251.
23.
Punkenburg E, et al: Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer. Gut 2016;65:1139-1150.
24.
Kelly CJ, et al: Fundamental role for HIF-1α in constitutive expression of human β defensin-1. Mucosal Immunol 2013;6:1110-1118.
25.
Sato T, et al: Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009;459:262-265.
26.
Peterson LW, Artis D: Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 2014;14:141-153.
27.
Wirtz S, Neufert C, Weigmann B, Neurath MF: Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007;2:541-546.
28.
Mottet C, Uhlig HH, Powrie F: Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003;170:3939-3943.
29.
Becker C, Fantini MC, Neurath MF: High resolution colonoscopy in live mice. Nat Protoc 2006;1:2900-2904.
30.
Wirtz S, Neurath MF: Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007;59:1073-1083.
31.
Wang C, et al: BATF is required for normal expression of gut-homing receptors by T helper cells in response to retinoic acid. J Exp Med 2013;210:475-489.
32.
Ciofani M, et al: A validated regulatory network for Th17 cell specification. Cell 2012;151:289-303.
33.
Mudter J, et al: IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo. Inflamm Bowel Dis 2011;17:1343-1358.
34.
Yang XO, et al: STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007;282:9358-9363.
35.
Oestreich KJ, Weinmann AS: Master regulators or lineage-specifying? Changing views on CD4+ T cell transcription factors. Nat Rev Immunol 2012;12:799-804.
36.
Bollig N, et al: Transcription factor IRF4 determines germinal center formation through follicular T-helper cell differentiation. Proc Natl Acad Sci U S A 2012;109:8664-8669.
37.
Brüstle A, et al: The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007;8:958-966.
38.
Staudt V, et al: Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 2010;33:192-202.
39.
Rengarajan J, et al: Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med 2002;195:1003-1012.
40.
Ise W, et al: The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat Immunol 2011;12:536-543.
41.
Jabeen R, et al: Th9 cell development requires a BATF-regulated transcriptional network. J Clin Invest 2013;123:4641-4653.
42.
Vasanthakumar A, et al: The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol 2015;16:276-285.
43.
Glasmacher E, et al: A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science 2012;338:975-980.
44.
Li P, et al: BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature 2012;490:543-546.
45.
Tussiwand R, et al: Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 2012;490:502-507.
46.
Übel C, et al: The activating protein 1 transcription factor basic leucine zipper transcription factor, ATF-like (BATF), regulates lymphocyte- and mast cell-driven immune responses in the setting of allergic asthma. J Allergy Clin Immunol 2014;133:198-206.e1-e9.
47.
Betz BC, et al: Batf coordinates multiple aspects of B and T cell function required for normal antibody responses. J Exp Med 2010;207:933-942.
48.
Kurachi M, et al: The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat Immunol 2014;15:373-383.
49.
Murphy TL, Tussiwand R, Murphy KM: Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat Rev Immunol 2013;13:499-509.
50.
Sawa S, et al: RORγt+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat Immunol 2011;12:320-326.
51.
Gordon SM, et al: The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012;36:55-67.
52.
Lugo-Villarino G, Maldonado-Lopez R, Possemato R, Penaranda C, Glimcher LH: T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci U S A 2003;100:7749-7754.
You do not currently have access to this content.